Catalent, Inc. (NYSE: CTLT), the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene therapies, and
consumer health products, today announced the appointment of Manja
Boerman, Ph.D., to the role of President, Cell & Gene Therapy,
effective June 1, 2020. In this new role, Dr. Boerman will lead all
of Catalent’s cell & gene therapy businesses worldwide. Dr.
Boerman will continue to report to Karen Flynn, Catalent’s
President of Biologics and Chief Commercial Officer.
Pete Buzy, who has led the Catalent Gene Therapy business since
the company’s acquisition of Paragon Bioservices in May 2019, will
be retiring but will remain with the company as Chairman of
Catalent Gene Therapy in an advisory capacity for the next 12
months to support Dr. Boerman as she transitions into her new role.
Dr. Boerman has already been leading Catalent’s cell therapy
business since the acquisition of MaSTherCell in February 2020.
Succeeding Dr. Boerman, Catalent also today announced the
appointment of Mario Gargiulo as Region President, Biologics –
Europe, as well as his appointment to the company’s Executive
Leadership Team.
“Working in concert and under Manja’s strong leadership, our
cell & gene therapy businesses will continue their substantial
growth and maturation over the past 12 months and further extend
our leadership position in the biotech industry,” said Karen Flynn,
President of Biologics and Chief Commercial Officer. “We are
excited to have high-performing talent in place to drive our cell
& gene therapy businesses to the next stage in their natural
evolution and development as we continue to expand and enhance our
innovative solutions for our customers and fulfil our mission in
helping people live better, healthier lives.”
Alessandro Maselli, Catalent’s President & Chief Operating
Officer, added, “I would like to thank Pete Buzy, under whose
guidance our gene therapy business has seen significant growth and
continuous investment to meet strong and growing demand for
adeno-associated virus vectors, next-generation vaccines, and
oncolytic viruses. I am glad that Pete will continue to provide his
invaluable experience and insights for the next 12 months for the
benefit of our customers and their patients, particularly while we
are in the midst of significant growth initiatives.”
Dr. Boerman joined Catalent in December 2019 with more than 20
years’ experience in biotech and pharmaceutical services, and
significant experience as a senior executive in start-up
environments and global late-stage clinical development for cell
therapy products. She most recently served as president of Aesica
Pharmaceuticals, a UK-based CDMO, and before that as CEO for a
Netherlands-based biotech and as Executive Director for Charles
Rivers Laboratories where she helped open a new biologics facility
in Boston. In addition, she served as president of Patheon
Biologics where she significantly grew the customer base and growth
path for biologics through organic activities and acquisitions.
Manja holds a doctorate in Biochemistry from the State University
of New York - Buffalo.
Since he joined Catalent in 2017, Mr. Gargiulo has held a number
of leadership roles, most recently as vice president of operations,
Biologics. He joined the company from Merck & Co.’s External
Manufacturing organization, having previously spent most of his
career at Bristol Myers Squibb in various operations leadership
roles including vice president of global pharmaceutical
manufacturing. In addition to his new role, he will continue to
oversee operations for all Catalent Biologics sites globally. Mario
holds a degree in Chemistry from the University of Naples,
Italy.
Notes for Editors
About Catalent
Catalent, Inc. (NYSE: CTLT), is the leading global provider of
advanced delivery technologies, development, and manufacturing
solutions for drugs, biologics, cell and gene therapies, and
consumer health products. With over 85 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
global clinical and commercial product supply. Catalent employs
over 13,500 people, including over 2,400 scientists and
technicians, at more than 40 facilities, and in fiscal year 2019
generated over $2.5 billion in annual revenue. Catalent is
headquartered in Somerset, New Jersey. For more information, visit
www.catalent.com
More products. Better treatments. Reliably supplied.™
Forward-Looking Statement
This release contains both historical and forward-looking
statements. All statements other than statements of historical fact
are, or may be deemed to be, forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally can be identified by the
use of statements that include phrases such as “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “plan,” “project,” “foresee,”
“likely,” “may,” “will,” “would” or other words or phrases with
similar meanings. Similarly, statements that describe the Company’s
objectives, plans or goals are, or may be, forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results could
vary materially from Catalent, Inc.’s expectations and projections.
Some of the factors that could cause actual results to differ
include, but are not limited to, the following: the current or
future effects of the COVID-19 pandemic on the Company's and its
clients' businesses; participation in a highly competitive market
and increased competition that may adversely affect the business of
the Company; demand for the Company’s offerings, which depends in
part on the Company’s customers’ research and development and the
clinical and market success of their products; product and other
liability risks that could adversely affect the Company’s results
of operations, financial condition, liquidity and cash flows;
failure to comply with existing and future regulatory requirements;
failure to provide quality offerings to customers could have an
adverse effect on the Company’s business and subject it to
regulatory actions and costly litigation; problems providing the
highly exacting and complex services or support required; global
economic, political and regulatory risks to the operations of the
Company; inability to enhance existing or introduce new technology
or service offerings in a timely manner; inadequate patents,
copyrights, trademarks and other forms of intellectual property
protections; fluctuations in the costs, availability, and
suitability of the components of the products the Company
manufactures, including active pharmaceutical ingredients,
excipients, purchased components and raw materials; changes in
market access or healthcare reimbursement in the United States or
internationally; fluctuations in the exchange rate of the U.S.
dollar against other currencies, including as a result of the
U.K.’s exit from the European Union; adverse tax legislative or
regulatory initiatives or challenges or adjustments to the
Company’s tax positions; loss of key personnel; risks generally
associated with information systems; inability to complete any
future acquisition or other transaction that may complement or
expand the Company’s business or divest of non-strategic businesses
or assets and difficulties in successfully integrating acquired
businesses and realizing anticipated benefits of such acquisitions;
risks associated with timely and successfully completing, and
correctly anticipating the future demand predicted for, capital
expansion projects at existing facilities, offerings and customers’
products that may infringe on the intellectual property rights of
third parties; environmental, health and safety laws and
regulations, which could increase costs and restrict operations;
labor and employment laws and regulations or labor difficulties,
which could increase costs or result in operational disruptions;
additional cash contributions required to fund the Company’s
existing pension plans; substantial leverage resulting in the
limited ability of the Company to raise additional capital to fund
operations and react to changes in the economy or in the industry;
and exposure to interest-rate risk to the extent of the Company’s
variable-rate debt preventing the Company from meeting its
obligations under its indebtedness. For a more detailed discussion
of these and other factors, see the information under the caption
“Risk Factors” in the Company’s Annual Report on Form 10-K for the
fiscal year ended June 30, 2019, filed August 27, 2019. All
forward-looking statements speak only as of the date of this
release or as of the date they are made, and Catalent, Inc. does
not undertake to update any forward-looking statement as a result
of new information or future events or developments except to the
extent required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200430005995/en/
Media: Chris Halling +44 (0)7580 041073
chris.halling@catalent.com
Richard Kerns +44 (0) 161 728 5880 richard@nepr.agency
Investors: Paul Surdez +1 (732) 537-6325
investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
From Apr 2023 to Apr 2024